第52届美国临床肿瘤学会年会（ASCO 2016）将于6月3～7日在美国芝加哥召开，本次会议将呈现诸多重磅研究结果和精彩报告。今天为大家整理ASCO日程--泌尿生殖系肿瘤篇，一起来关注前列腺癌和非前列腺癌泌尿生殖系肿瘤领域有哪些重点报告吧！
泌尿生殖系肿瘤（前列腺癌）篇
6月3日 2:45 PM - 4:00 PM
地点：S406
教育专场-前列腺癌寡转移：治疗还是观察？
寡转移疾病的定义和管理
Definition and Management of Oligometastatic Disease
Christopher Sweeney
Dana-Farber Cancer Institute， Harvard Cancer Center
6月3日 4:45 PM - 6:00 PM
地点：S406
教育专场-当代前列腺癌主动监测：需要更好的影像学和分子检测吗？
分子标志物在危险度分级中的作用
The Role of Molecular Biomarkers in Risk Stratification
Edward M. Schaeffer
Johns Hopkins University School of Medicine
6月4日 8:00 AM - 9:15 AM
地点：Arie Crown Theater
教育专场-晚期前列腺癌的精准医学：认识基因组学、雄激素受体剪接变异体和影像学生物标志物
预后性和预测性循环生物标志物的进展
Development of Prognostic and Predictive Circulating Biomarkers
Gerhardt Attard
The Institute of Cancer Research and The Royal Marsden Hospital
ARv7作为一种临床生物标志物
ARv7 As a Clinical Biomarker
Emmanuel S. Antonarakis
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
6月4日 1:15 PM - 2:30 PM
地点：S404
教育专场：不断发展的前列腺癌筛查推荐
过去和未来：2012年美国预防服务组前列腺筛查推荐
Past and Future: The Impact of the 2012 U.S. Preventive Services Task Force Prostate Screening Recommendations.
Otis W. Brawley
American Cancer Society
前列腺癌筛查和早期发现的未来
Future of Prostate Cancer Screening and Early Detection
Ian Murchie Thompson
The University of Texas Health Science Center at San Antonio
6月5日 11:30 AM - 12:45 PM
地点：E253D
教授见面会：镭-223在去势抵抗性前列腺癌管理中的作用
Radium-223 in the Management of Castration-Resistant Prostate Cancer
Chris C. Parker
Royal Marsden NHS Foundation Trust and The Institute of Cancer Research
6月6日 8:00 AM - 11:00 AM
地点：Hall D2
口头报告
Abstract 5000
The PROMIS study: A paired-cohort， blinded confirmatory study evaluating the accuracy of multi-parametric MRI and TRUS biopsy in men with an elevated PSA.
Abstract 5005
PRINCE: A phase III study comparing intermittent docetaxel therapy versus continuous docetaxel therapy in patients with castration-resistant prostate cancer.
泌尿生殖系肿瘤（非前列腺癌）篇
6月3日 2:45 PM - 4:00 PM
地点：E253D
教授见面会：上尿路移行细胞癌的系统治疗和手术治疗注意事项
上尿路移行细胞癌：系统治疗和手术注意事项
Upper Urinary Tract Transitional Cell Carcinoma: Systemic and Surgical Considerations
Viraj A. Master
Winship Cancer Institute of Emory University
6月3日 4:45 PM - 6:00 PM
地点：E253B
肿瘤临床问题专场-睾丸癌：一例多学科病例讨论
肿瘤内科医生观点
A Medical Oncologist Perspective
George J. Bosl
Memorial Sloan Kettering Cancer Center
外科医生观点
A Surgeon Perspective
Axel Heidenreich
Cologne University
放射肿瘤科医生观点
A Radiation Oncologist Perspective
Padraig Richard Warde
Princess Margaret Cancer Centre
6月4日 1:15 PM - 2:30 PM
地点：S406
教育专场-老年膀胱癌患者：来自外科、肿瘤内科和放射肿瘤科医生的观点
老年膀胱癌患者的治疗决策：平衡风险和获益
Decision Making for Treatment of Older Patients With Bladder Cancer: Balancing Risks and Benefits
Supriya Gupta Mohile
University of Rochester Medical Center
6月5日 8:00 AM - 11:00 AM
地点：Hall D2
口头报告
Abstract LBA4500
Atezolizumab (atezo) as first-line (1L) therapy in cisplatin-ineligible locally advanced/metastatic urothelial carcinoma (mUC): Primary analysis of IMvigor210 cohort 1.
Abstract 4503
Limited versus extended pelvic lymphadenectomy in patients with bladder cancer undergoing radical cystectomy: Survival results from a prospective， randomized trial (LEA AUO AB 25/02).
Abstract 4507
Long-term overall survival (OS) with nivolumab in previously treated patients with advanced renal cell carcinoma (aRCC) from phase I and II studies.
6月6日 11:30 AM - 12:45 PM
地点：S406
教育专场-肾细胞癌：系统治疗、TKI进展和免疫肿瘤学
肾细胞癌新靶向治疗的作用和组合
The Role and Combinations of New Targeted Treatments for Renal Cell Carcinoma
Brian I. Rini
Cleveland Clinic Taussig Cancer Institute
6月6日 1:15 PM - 2:30 PM
地点：S406
教育专场-肾细胞癌减瘤手术辩论会
支持减瘤手术
Cytoreductive Nephrectomy: Pro
Jose A. Karam
The University of Texas MD Anderson Cancer Center
反对减瘤手术
Cytoreductive Nephrectomy: Con.
Ulka N. Vaishampayan
Karmanos Cancer Institute
6月7日 9:45 AM - 11:15 AM
地点：S100bc
临床科学研讨会：DNA修复在泌尿生殖系肿瘤管理中的作用
Abstract 5009
Inherited mutations in DNA repair genes in men with metastatic castration resistant prostate cancer.
Abstract 5010
Co-targeting androgen receptor (AR) and DNA repair: A randomized ETS gene fusion-stratified trial of abiraterone + prednisone (Abi) +/- the PARP1 inhibitor veliparib for metastatic castration-resistant prostate cancer (mCRPC) patients (pts) (NCI9012)-A University of Chicago phase II consortium trial.
Abstract 5011
Correlation of DNA damage response (DDR) gene alterations with response to neoadjuvant (neo) dose-dense gemcitabine and cisplatin (ddGC) in urothelial carcinoma (UC).
京公网安备 11010502033352号